Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF

Clinical Rheumatology

Volumn 26, Issue 11, 2007, Pages 1883-1889

  Silveira, Ines G ^a   Burlingame, R W ^b   von Muhlen C A ^a   Bender, A L ^a   Staub, H L ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

Anti CCP antibodies; Anti citrullinated peptide antibodies; Citrullinated proteins; Likelihood ratio; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE; PEPTIDE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; FEMALE; HUMAN; INFORMED CONSENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

AGED; ANTIBODIES; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 34948865807     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0601-6     Document Type: Article

References (35)

1. Van der Heijde D (1995) Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 34:74-78
2. O'Dell JR (2002) Treating rheumatoid arthritis early: A window of opportunity? Arthritis Rheum 46:283-285
3. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
4. Ostergaard M, Ejbjerg B, Szkudlarek M (2005) Imaging in early rheumatoid arthritis: Roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography. Best Pract Res Clin Rheumatol 19:91-116
5. Schumacher HR, Pessler F, Chen LX (2003) Diagnosing early rheumatoid arthritis (RA). What are the problems and opportunities? Clin Exp Rheumatol 21(5 Suppl 31):S15-S19 S15-S19
6. Goldbach-Mansky R, Lee J, McCoy A et al (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2(3):236-243
7. Schellekens GA, de Jong BA, van den Hoogen FH et al (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101(1):273-281
8. Nienhuis RL, Mandema E (1964) A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 23:302-305
9. Young BJ, Mallya RK, Leslie RD et al (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2(6182):97-99
10. Silveira IG, Keiserman MW, vonMühlen CA (2000) Clinical and laboratorial study of antiperinuclear factor in rheumatoid arthritis. Rev Bras Reumatol 40:159-167
11. Sebbag M, Simon M, Vincent C et al (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95(6):2672-2679
12. Simon M, Girbal E, Sebbag M et al (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 92(3):1387-1393
13. Girbal-Neuhauser E, Durieux JJ, Arnaud M et al (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162(1):585-594
14. Union A, Meheus L, Humbel RL et al (2002) Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 46(5):1185-1195
15. Serre G (2001) Autoantibodies to filaggrin/deiminated fibrin (AFA) are useful for the diagnosis and prognosis of rheumatoid arthritis, and are probably involved in the pathophysiology of the disease. Joint Bone Spine 68(2):103-105
16. Dubucquoi S, Solau-Gervais E, Lefranc D et al (2004) Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63(4):415-419
17. Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C et al (2004) Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol 33(4):218-220
18. De Rycke L, Peene I, Hoffman IE et al (2004) Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63(12):1587-1593
19. Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43(1):155-163
20. Bas S, Perneger TV, Seitz M et al (2002) Diagnostic tests for rheumatoid arthritis: Comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 41(7):809-814
21. Bizzaro N, Mazzanti G, Tonutti E et al (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47(6):1089-1093
22. Sauerland U, Becker H, Seidel M et al (2005) Clinical utility of the anti-CCP assay: Experiences with 700 patients. Ann N Y Acad Sci 1050:314-318
23. Ronnelid J, Wick MC, Lampa J et al (2005) Longitudinal analysis of anti-citrullinated protein/peptide antibodies (anti-CP) during 5 year follow-up in early rheumatoid arthritis: Anti-CP status is a stable phenotype that predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64(12):1744-1749
24. Kroot EJ, de Jong BA, van Leeuwen MA et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43(8):1831-1835
25. Solanki K, Spellerberg M, Chapman P et al (2004) Anti-cyclic citrullinated antibodies: Complementary to IgM rheumatoid factor in the early diagnosis of rheumatoid arthritis. N Z Med J 117(1203):U1097
26. Moons KG, Biesheuvel CJ, Grobbee DE (2004) Test research versus diagnostic research. Clin Chem 50(3):473-476
27. Deeks JJ, Altman DG (2004) Diagnostic tests 4: Likelihood ratios. BMJ 329(7458):168-169
28. Wolfe F (1998) A comparison of IgM rheumatoid factor by nephelometry and latex methods: Clinical and laboratory significance. Arthritis Care Res 11(2):89-93
29. Knight RK, Pritchard MH (1982) Nephelometry compared with differential antibody titre in routine rheumatoid factor measurements. Ann Rheum Dis 41(4):426-430
30. Sackett DL, Haynes RB, Tugwell P (1985) Clinical epidemiology: A basic science for clinical medicine. Little, Brown & Co, Boston
31. Gallagher EJ (1998) Clinical utility of likelihood ratios. Ann Emerg Med 31(3):391-397
32. Radack KL, Rouan G, Hedges J (1986) The likelihood ratio. An improved measure for reporting and evaluating diagnostic test results. Arch Pathol Lab Med 110(8):689-693
33. Wolfe F, Cathey MA, Roberts FK (1991) The latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 34(8):951-960
34. Visser H, Gelinck LB, Kampfraath AH et al (1996) Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 55(3):157-161
35. Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48(10):2741-2749